Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Hepregen Launches First Human HepatoPac™ Assay Kit

Published: Wednesday, March 26, 2014
Last Updated: Wednesday, March 26, 2014
Bookmark and Share
Application-directed kit provides information useful in predicting potential drug-induced liver injury.

At the Society of Toxicology's 53rd Annual Meeting, Hepregen Corporation has announced the commercial launch of the company's first HepatoPacT kit designed specifically for toxicology applications.

The kit contains one or more standard 96-well tissue culture plates featuring specially configured micro-patterned human liver cells co-cultured with stromal cells.

The liver cells (hepatocytes) on these plates mirror the behavior of liver cells in the body, enabling scientists to generate data that can be useful for prediction of toxic responses to chemical agents, including drug candidates.

The application-directed platform also provides a tool for the study of the mechanisms leading to such responses.

Jack McGeehan, Hepregen's Vice President of Operations, stated, "The hepatocytes in this specially configured product remain viable for weeks at a time, and they exhibit full functionality during this extended time period. This longevity means that the product may be useful for the study of chronic exposure to drug candidates and other new chemical entities, reflecting what likely could occur when humans are exposed to such agents for long periods. Because the hepatocytes also are fully active metabolically, investigators can evaluate toxicity associated with metabolites of these chemical entities in a single experiment."

Dr. Vincent Zurawski, Hepregen's Chief Executive Officer, stated, "This new kit is the first version of a human HepatoPacT application-directed kit that is focused on the in vitro toxicology market. In the coming months, aiming to serve this growing market, Hepregen also expects to be introducing more advanced HepatoPacT toxicology products, some of which are currently in development. The launch adds another product to the company's portfolio, which includes human, rat, monkey, human triple-donor and rat-human HepatoPacT application-directed kits for metabolite identification and profiling, and a recently introduced human kit to evaluate metabolic stability."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

SOLVO Biotechnology and Hepregen Execute Co-Marketing Agreement
Agreement provides for European sales of Hepregen's HepatoPac® and HepatoMune™ proprietary products by SOLVO and provision of services using these products.
Wednesday, June 24, 2015
Hepregen Announces Appointment of Dr. Michael Holsapple
Appointment adds respected leader in toxicology to Hepregen’s senior management team, reflecting ongoing commitment of Hepregen’s strategic investor, Battelle Memorial Institute.
Wednesday, August 07, 2013
Scientific News
Fighting Cancer with Sticky Nanoparticles
Treatment that uses bioadhesive nanoparticles drug carriers proved more effective than conventional treatments for certain cancers.
Stem Cell ‘Heart Patch’ Almost Perfected
Scientists aiming to perfect and test 3D "heart patches" in animal model, last hurdle before human patients.
Smart Material Hunts Cancers
Team has created smart material that locates and images cancer or tumour sites in tissue.
Targeting Fat to Treat Cancer
Researchers develop novel cancer treatment that halts fat synthesis in cells, stunting tumors.
Reprogramming Lymph Nodes to Fight MS
Bioengineers work to reprogram lymph node function to fight multiple sclerosis.
Arms Race with a Superbug
Scientists have discovered that increased risk of superbug infection can be directly casued by immune system response to invading bacteria.
Genes Essential to Life Discovered
Genes critical for life are discovered in humans and mice as part of large-scale phenotyping study.
High-Capacity Nanoparticles
New type of nanoparticle can now have three or more drugs packaged within it, allowing for customised cancer therapy.
Manipulation of Liquid Crystals Could Help Control Drug-Delivery Process
Computer modeling, real-world testing yields new method.
Puttng Cells Through Their Paces
An obstacle course for human lung cells could be the answer for better testing the effectiveness of potential new drugs.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!